Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.09
- Piotroski Score 2.00
- Grade Equal-Weight
- Symbol (AGLE)
- Company Aeglea BioTherapeutics, Inc.
- Price $12.01
- Changes Percentage (6.66%)
- Change $0.75
- Day Low $10.69
- Day High $12.34
- Year High $24.00
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/04/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$74.15
- Trailing P/E Ratio -0.16196898179366
- Forward P/E Ratio -0.16196898179366
- P/E Growth -0.16196898179366
- Net Income $-83,815,000
Income Statement
Quarterly
Annual
Latest News of AGLE
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Eagles predictions at NFL midseason: Saquon Barkley breaks records, Nick Sirianni stays
Jordan Mailata expressed frustration with dwelling on the past, emphasizing the Eagles' forward progress. Despite his injury, the team is thriving in 2024, with a promising outlook and potential recor...
By The New York Times | 13 hours ago -
Seattle U set for road matchup with the Eastern Washington Eagles
Eastern Washington Eagles will face Seattle U Redhawks in Cheney, Washington. The Eagles had a strong home record last season, while the Redhawks showed good shooting percentages....
By AP NEWS | 14 hours ago -
Saquon Barkley uses acrobatic runs to power the Eagles to a four-game winning streak after their bye
Saquon Barkley's incredible athleticism and performances have propelled the Eagles to a four-game winning streak. His impact on the team's offense, along with improvements in turnovers and short-yarda...
By AP NEWS | 1 day ago
